Ad is loading...
PGEN
Price
$0.90
Change
+$0.06 (+7.14%)
Updated
Nov 21 closing price
96 days until earnings call
YMAB
Price
$10.10
Change
-$0.44 (-4.17%)
Updated
Nov 21 closing price
90 days until earnings call
Ad is loading...

PGEN vs YMAB

Header iconPGEN vs YMAB Comparison
Open Charts PGEN vs YMABBanner chart's image
Precigen
Price$0.90
Change+$0.06 (+7.14%)
Volume$795.76K
CapitalizationN/A
Y-mAbs Therapeutics
Price$10.10
Change-$0.44 (-4.17%)
Volume$245.87K
CapitalizationN/A
PGEN vs YMAB Comparison Chart
Loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
PGEN vs. YMAB commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a Sell and YMAB is a StrongBuy.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (PGEN: $0.90 vs. YMAB: $10.10)
Brand notoriety: PGEN and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PGEN: 103% vs. YMAB: 99%
Market capitalization -- PGEN: $264.43M vs. YMAB: $452.37M
PGEN [@Biotechnology] is valued at $264.43M. YMAB’s [@Biotechnology] market capitalization is $452.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PGEN’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • PGEN’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, YMAB is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PGEN’s TA Score shows that 3 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • PGEN’s TA Score: 3 bullish, 6 bearish.
  • YMAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than PGEN.

Price Growth

PGEN (@Biotechnology) experienced а +2.27% price change this week, while YMAB (@Biotechnology) price change was -12.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.

Reported Earning Dates

PGEN is expected to report earnings on Feb 26, 2025.

YMAB is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-3.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($452M) has a higher market cap than PGEN($264M). YMAB YTD gains are higher at: 48.094 vs. PGEN (-32.619). YMAB has higher annual earnings (EBITDA): -27.87M vs. PGEN (-136.11M). YMAB has more cash in the bank: 68.1M vs. PGEN (28.6M). YMAB has less debt than PGEN: YMAB (1.08M) vs PGEN (5.75M). YMAB has higher revenues than PGEN: YMAB (84.6M) vs PGEN (3.96M).
PGENYMABPGEN / YMAB
Capitalization264M452M58%
EBITDA-136.11M-27.87M488%
Gain YTD-32.61948.094-68%
P/E RatioN/AN/A-
Revenue3.96M84.6M5%
Total Cash28.6M68.1M42%
Total Debt5.75M1.08M535%
FUNDAMENTALS RATINGS
PGEN vs YMAB: Fundamental Ratings
PGEN
YMAB
OUTLOOK RATING
1..100
855
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
8461
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
11n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (53) in the Pharmaceuticals Major industry is in the same range as PGEN (57) in the null industry. This means that YMAB’s stock grew similarly to PGEN’s over the last 12 months.

YMAB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that YMAB’s stock grew similarly to PGEN’s over the last 12 months.

YMAB's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as PGEN (98) in the null industry. This means that YMAB’s stock grew similarly to PGEN’s over the last 12 months.

YMAB's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as PGEN (84) in the null industry. This means that YMAB’s stock grew similarly to PGEN’s over the last 12 months.

YMAB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that YMAB’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PGENYMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 17 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUIZX36.060.47
+1.32%
AB Equity Income Z
DAFGX44.910.46
+1.03%
Dunham Focused Large Cap Growth A
NSFGX12.770.08
+0.63%
Natixis Target Retirement 2035 N
UINQX52.120.19
+0.37%
Victory Nasdaq 100 Index Institutional
GSIKX17.95N/A
N/A
Goldman Sachs International Eq Inc Instl

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+7.91%
CRSP - PGEN
55%
Loosely correlated
-2.05%
NTLA - PGEN
53%
Loosely correlated
+5.18%
BEAM - PGEN
52%
Loosely correlated
-3.72%
DNLI - PGEN
51%
Loosely correlated
-0.82%
RCKT - PGEN
50%
Loosely correlated
-1.92%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with RCKT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-4.17%
RCKT - YMAB
41%
Loosely correlated
-1.92%
IDYA - YMAB
40%
Loosely correlated
+4.15%
PLRX - YMAB
38%
Loosely correlated
+0.94%
SNDX - YMAB
37%
Loosely correlated
-2.19%
PGEN - YMAB
37%
Loosely correlated
+7.91%
More